Microglia-mediated neuroinflammation plays a critical role in Corticobasal Degeneration (CBD), a 4-repeat (4R) tauopathy characterized by asymmetric cortical dysfunction and basal ganglia degeneration. As the resident immune cells of the central nervous system, microglia undergo significant activation in CBD, contributing to both disease progression and compensatory responses. This page explores microglial biology in CBD, contrasts it with Alzheimer's disease (AD) and Progressive Supranuclear Palsy (PSP), and discusses therapeutic implications.
Microglia in CBD exhibit:
- Chronic activation: Persistent pro-inflammatory responses in affected brain regions
- TREM2 involvement: TREM2 variants influence disease risk and progression
- DAM-like phenotypes: Disease-associated microglia signatures similar to other neurodegenerative conditions
- Tau phagocytosis: Attempted but often ineffective clearance of tau aggregates
- Interactions with Astrocytes: Complex neuroinflammatory crosstalk
While TREM2 variants are most strongly associated with Alzheimer's disease, emerging evidence suggests:
- TREM2 expression: Elevated TREM2 levels in CBD brain tissue
- Variant effects: Some TREM2 variants may modify CBD risk or progression
- Therapeutic relevance: TREM2 remains a potential therapeutic target
flowchart TD
A["TREM2 Activation"] --> B["DAP12 ITAM Signaling"]
B --> C["SYK Activation"]
C --> D{"Downstream Pathways"}
D --> E["PI3K/AKT - Cell Survival"]
D --> F["MAPK/ERK - Gene Expression"]
D --> G["NF-κB - Inflammation"]
D --> H["Calcium Signaling - Phagocytosis"]
E --> I["Microglial Survival"]
F --> J["Inflammatory Response"]
G --> J
H --> K["Phagocytic Activity"]
K --> L["Tau Clearance"]
L --> M{"Adequate Clearance?"}
M -->|"Yes"| N["Neuroprotection"]
M -->|"No"| O["Tau Accumulation"]
O --> P["Disease Progression"]
Disease-associated microglia (DAM) in CBD share features with other neurodegenerative conditions:
- Stage 1 DAM: TREM2-independent activation
- Stage 2 DAM: TREM2-dependent full activation
- Upregulated genes: APOE, TREM2, ITGAX (CD11c), CTSD (cathepsin D)
Microglial responses vary by affected brain region in CBD:
- Prominent microglial activation in motor and sensory cortices
- Association with cortical neuron loss
- Reactive astrocytes adjacent to activated microglia
- Striatal microgliosis correlating with GABAergic neuron loss
- Substantia nigra microglial involvement similar to PSP
- TREM2-mediated microglial activation
- DAM phenotype development
- APOE involvement in microglial responses
- Neuroinflammatory cytokine production
| Feature |
Alzheimer's Disease |
Corticobasal Degeneration |
| Primary pathology |
Amyloid-beta + tau |
4R tau only |
| Microglial trigger |
Amyloid plaques |
Tau aggregates |
| Plaque-associated microglia |
Prominent |
Not applicable |
| TREM2 variant risk |
Strong (2-4x) |
Less defined |
| Timing of inflammation |
Early contributor |
Later contributor? |
As another 4R tauopathy, CBD shares microglial features with PSP:
- Similar tau-driven microglial activation patterns
- Comparable regional distribution of inflammation
- TREM2 involvement in both conditions
- Shared therapeutic targets
- IL-1β: Elevated in CBD, contributes to neuronal dysfunction
- IL-6: Increased expression in affected regions
- TNF-α: Promotes neurotoxicity and blood-brain barrier disruption
Microglia generate reactive oxygen species (ROS) that:
- Contribute to lipid peroxidation
- Damage Neurons directly
- Exacerbate tau pathology
- TREM2 agonists: Enhance microglial phagocytosis
- Anti-TREM2 antibodies: Currently in development for AD, potential for CBD
- sTREM2 modulation: Soluble TREM2 as biomarker and therapeutic target
- Minocycline: Antibiotic with anti-microglial effects (clinical trials in CBD)
- NSAIDs: Mixed results in tauopathies
- IL-1 receptor antagonists: Targeting specific inflammatory pathways
- CSF1R inhibitors: Reduce microglial proliferation
- TREM2-LXR pathway: Microglia state editing approaches
¶ Microglial Development and Origin
Microglia originate from embryonic yolk sac progenitors and colonize the brain during development:
- Primitive hematopoiesis: Early microglial progenitors
- Postnatal expansion: Proliferation and brain colonization
- Adult maintenance: Self-renewal under normal conditions
- Disease response: Activated proliferation in neurodegeneration
Microglia exhibit diverse activation states in CBD:
Surveillance State:
- Resting but alert morphology
- Continuous process extension
- Rapid response to perturbations
Activated States:
- Pro-inflammatory (M1-like): Cytokine production
- Anti-inflammatory (M2-like): Tissue repair
- Disease-associated: Neurodegeneration-specific
Hybrid States:
- Context-dependent phenotypes
- Intermediate activation levels
- Regional variation
Microglial morphology changes in CBD:
- Cell body enlargement: Increased soma size
- Process retraction: Reduced branching
- Filopodia formation: New process extensions
- Phagocytic cups: Engulfment preparations
These morphological changes correlate with functional shifts in microglial activity.
The frontal cortex shows prominent microglial activation in CBD:
- Motor cortex: Associated with motor symptoms
- Premotor cortex: Correlates with apraxia
- Prefrontal cortex: Linked to executive dysfunction
- Distribution: Often asymmetric, matching clinical phenotype
Microglial responses in basal ganglia regions:
- Putamen: Highest activation, correlates with rigidity
- Caudate nucleus: Moderate activation
- Globus pallidus: Variable involvement
- Substantia nigra: Similar to PSP pattern
Microglia in white matter tracts:
- Corpus callosum: Interhemispheric communication
- Internal capsule: Motor pathway involvement
- Superior longitudinal fasciculus: Cognitive connections
TREM2 activates multiple downstream signaling cascades:
Phosphatidylinositol 3-Kinase (PI3K) Pathway:
- AKT activation
- Cell survival signaling
- Anti-apoptotic effects
Mitogen-Activated Protein Kinase (MAPK) Pathway:
- ERK1/2 activation
- Gene expression modulation
- Inflammatory response regulation
Nuclear Factor kappa B (NF-κB) Pathway:
- Pro-inflammatory gene transcription
- Cytokine production
- Cell survival
Multiple cytokines contribute to CBD neuroinflammation:
Pro-inflammatory cytokines:
- Interleukin-1β (IL-1β): Neuronal dysfunction
- Interleukin-6 (IL-6): Acute phase response
- Tumor necrosis factor-alpha (TNF-α): Neurotoxicity
Anti-inflammatory cytokines:
- Interleukin-10 (IL-10): Neuroprotection
- Transforming growth factor-beta (TGF-β): Repair
Chemokines:
- CCL2: Monocyte recruitment
- CXCL12: Microglial migration
The complement system is heavily involved:
- C1q: Synaptic pruning initiation
- C3/C3a: Microglial activation
- C4b: Opsonization
- CR3: Phagocytic clearance
Tau protein directly activates microglia:
- Extracellular tau: Released from neurons
- Tau oligomers: More potent activators
- Tau fibrils: Chronic activation
- Post-translational modifications: Phospho-tau effects
Microglia attempt to clear tau:
- Phagocytosis: Engulfment of tau aggregates
- Autophagy: Intracellular degradation
- Proteasomal degradation: Ubiquitin-proteasome system
- Limitations: Incomplete clearance in CBD
Ineffective tau clearance leads to:
- Tau accumulation: In neurons and glia
- Microglial exhaustion: Dysfunctional phenotype
- Chronic inflammation: Perpetuated damage
- Spread: Templated propagation
Both are 4R tauopathies with microglial involvement:
Shared features:
- 4R tau pathology
- Microglial activation
- Regional specificity
- TREM2 involvement
CBD-specific:
- Asymmetric involvement
- Cortical predominance
- TREM2 variant associations
As a 3R tauopathy, Pick's disease differs:
- Different tau isoform
- Less prominent inflammation
- Distinct regional distribution
- Different treatment responses
Comparing microglial roles across proteinopathies:
| Feature |
CBD |
AD |
| Primary trigger |
Tau |
Amyloid + Tau |
| Inflammation timing |
Later |
Early |
| TREM2 importance |
Moderate |
High |
| DAM phenotype |
Present |
Prominent |
| Therapeutic target |
Tau + Inflammation |
Amyloid + Inflammation |
Microglial activation can be visualized:
- TSPO PET: 18 kDa translocator protein
- PK11195: First-generation ligand
- PBR28: Second-generation, higher affinity
- Limitations: Variable binding, nonspecific
Structural MRI findings:
- Atrophy patterns: Match microglial regions
- White matter changes: Associated inflammation
- Regional specificity: CBD vs. PSP differences
Emerging microglial imaging:
- TREM2-targeting tracers: In development
- Fluorinated ligands: Improved specificity
- Multiple targets: Beyond TSPO
Existing treatments targeting microglia:
Anti-inflammatory:
- Minocycline: Antibiotic with anti-microglial effects
- NSAIDs: Non-selective inflammation reduction
- Corticosteroids: Short-term use
Modulatory:
- CSF1R inhibitors: Reduce microglial numbers
- TREM2 modulators: Fine-tune activation
Disease-modifying:
- Anti-tau antibodies: Reduce tau burden
- Anti-aggregation drugs: Prevent spread
New therapeutic approaches:
TREM2-targeted:
- Anti-TREM2 antibodies: Agonists
- TREM2 small molecule modulators
- Gene therapy approaches
Microglial state editing:
- LXR agonists: Anti-inflammatory shift
- PPAR agonists: Metabolic modulation
- HDAC inhibitors: Epigenetic changes
Cell replacement:
- Microglial transplantation
- iPSC-derived microglia
- Bone marrow transplantation
Recent and ongoing trials:
- Minocycline in CBD: Phase II completed
- TREM2 antibodies in AD: Phase I/II ongoing
- Anti-tau therapies: Expanding to CBD
- Neuroinflammation modulators: Various targets
Microglial biomarkers:
- CSF cytokines: IL-1β, IL-6, TNF-α
- CSF TREM2: Soluble TREM2 levels
- Neurofilament light chain: Disease activity
- Imaging markers: TSPO PET
Areas requiring investigation:
- Tau-microglia crosstalk: Detailed mechanisms
- Microglial heterogeneity: Regional differences
- Sex differences: Gender effects on microglia
- Age effects: Aging-related changes
Future treatment directions:
- Combination therapies: Multi-target approaches
- Personalized medicine: Biomarker-guided treatment
- Timing: Early intervention importance
- Delivery: Blood-brain barrier penetration